Advanced search
Publication Cover
Seminars in Ophthalmology Volume 38, 2023 - Issue 6
Submit an article Journal homepage
509
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Real-World Investigation of Impact of Retinal Fluid in Treatment Naïve Eyes Treated with Anti-VEGF for Neovascular Age-Related Macular Degeneration

Meri Vukicevica Discipline of Orthoptics, La Trobe University, Melbourne, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0887-6248View further author information
ORCID Icon,
Myra B. McGuinnessb Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia;c Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0002-5422-040XView further author information
ORCID Icon &
Nandor Jarossd Australian Eye Specialists, Wyndham & Bacchus Marsh, AustraliaView further author information
Pages 592-597 | Received 09 Sep 2022, Accepted 30 Jan 2023, Published online: 09 Feb 2023

References

  • Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933–943. doi:10.1016/S0161-6420(92)31871-8.
  • Mursch-Edlmayr AS, Luft N, Podkowinski D, Ring M, Schmetterer L, Bolz M. Effects of three intravitreal injections of aflibercept on the ocular circulation in eyes with age-related maculopathy. Br J Ophthalmol. 2020;104(1):53–57. doi:10.1136/bjophthalmol-2019-313919.
  • Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481.
  • Gillies MC, Campain A, Barthelmes D, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2015;122(9):1837–1845. doi:10.1016/j.ophtha.2015.05.010.
  • Holz F, Minnella A, Tuli R, et al. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: real-world outcomes from the LUMINOUS study. PLoS ONE. 2020;15(12):1–17.doi:10.1371/journal.pone.0244183.
  • Wachtlin J, Eter N, Hasanbasic Z, et al. Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study. Graefes Arch Clin Exp Ophthalmol. 2021;259(3):601–611. doi:10.1007/s00417-020-04803-8.
  • Holekamp NM, Sadda S, Sarraf D, et al. Effect of residual retinal fluid on visual function in ranibizumab-treated neovascular age-related macular degeneration. Am J Ophthalmol. 2022;233:8–17. doi:10.1016/j.ajo.2021.06.029.
  • Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1–24. doi:10.1016/j.preteyeres.2015.07.007.
  • Gillies MC, Walton R, Liong J, et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project. Retina. 2014;34(1):188–195. doi:10.1097/IAE.0b013e318296b271.
  • WHO. International Classification of Diseases for Mortality and Morbidity Statistics [11th Revision]. World Health Organisation; 2022. https://www.who.int/standards/classifications/classification-of-diseases
  • Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908.
  • Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65.e5. doi:10.1016/j.ophtha.2008.10.018.
  • Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006.
  • Dugel P, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017.
  • Weber M, Velasque L, Coscas F, Faure C, Aubry I, Cohen SY. Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study. BMJ Open Ophthalmol. 2019;4(1):e000109. doi:10.1136/bmjophth-2017-000109.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.